Clinical Trial Update: Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating isotretinoin with or without dinutuximab, aldesleukin, and sargramostim after stem cell transplant in patients with neuroblastoma; re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Aldesleukin (interleukin-2)
• ISOTRETINOIN (Isotretinoin)
• dinutuximab (dinutuximab)
• sargramostim (sargramostim)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma | Phase 3 | Status: COMPLETED | Results posted: 2017-03-29